The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients
- PMID: 26112140
- PMCID: PMC4482272
- DOI: 10.1186/s12863-015-0234-8
The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients
Abstract
Background: Interleukin-10 and tumor necrosis factor α play an important role in breast carcinogenesis. Genes, encoding those two cytokines, contain single nucleotide polymorphisms, which are associated with differential levels of gene transcription. This study analyzes single nucleotide polymorphisms in interleukin 10 and tumor necrosis factor α genes and their contribution to breast cancer phenotype, lymph node status and survival in a group of young Lithuanian women with early-stage breast cancer patients.
Results: We genotyped 100 premenopausal Eastern European (Lithuanian) patients with stage I-II breast cancer, ≤ 50 years old at the time of diagnosis, for interleukin 10 -592A > C, -819C > T and -1082A > G and tumor necrosis factor α -308G > A single nucleotide polymorphisms in the gene promoter region. We used the polymerase chain reaction, namely a restriction fragment length polymorphism method, for a SNP analysis. All genotypes were in Hardy-Weinberg equilibrium and had the same distribution as the HapMap CEU population. Holders of IL10 -592A > C heterozygous IL10 -592 AC genotype had a higher probability of estrogen receptor positive breast cancer phenotype than homozygous variants (P = 0.017). Phased ACC haplotype of IL10 polymorphisms was associated with younger age of diagnosis (P = 0.017). Of all the tested single nucleotide polymorphisms, only TNFα -308G > A has revealed a prognostic capability for breast cancer survival. GA genotype carriers, compared to GG, showed a significant disadvantage in progression-free survival (P = 0.005, adjusted hazard ratio (HR) = 4.631, 95 % confidence interval (CI) = 1.587 - 13.512), metastasis-free survival (P = 0.010, HR = 4.708, 95 % CI = 1.445 - 15.345) and overall survival (P = 0.037, HR = 4.829, 95 % CI = 1.098 - 21.243).
Conclusions: According to our data, IL10 -1082A > G, -819 T > C, -592A > C polymorphisms and phased haplotypes have not revealed a prognostic value for breast cancer. On the contrary, the TNFα -308 polymorphism might modulate the risk and contribute to the identification of patients at a higher risk of breast cancer recurrence, metastasis and worse overall survival among young Lithuanian early-stage breast cancer patients.
Figures




Similar articles
-
Genetic polymorphisms in tumor necrosis factor alpha and interleukin-10 are associated with an increased risk of cervical cancer.Int Immunopharmacol. 2019 Jan;66:154-161. doi: 10.1016/j.intimp.2018.11.015. Epub 2018 Nov 16. Int Immunopharmacol. 2019. PMID: 30453149 Free PMC article.
-
Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population.J Exp Clin Cancer Res. 2010 Jun 17;29(1):72. doi: 10.1186/1756-9966-29-72. J Exp Clin Cancer Res. 2010. PMID: 20553628 Free PMC article.
-
Genetic Polymorphism in TNF-α-308 G/A and TNF-β +252 A/G, as Prognostic Biomarker in Breast Cancer Patients among Indian Population.Asian Pac J Cancer Prev. 2020 Feb 1;21(2):301-308. doi: 10.31557/APJCP.2020.21.2.301. Asian Pac J Cancer Prev. 2020. PMID: 32102503 Free PMC article.
-
Interleukin-10 promoter 1082/-819/-592 polymorphisms are associated with asthma susceptibility in Asians and atopic asthma: a meta-analysis.Lung. 2014 Feb;192(1):65-73. doi: 10.1007/s00408-013-9519-8. Epub 2013 Oct 27. Lung. 2014. PMID: 24162871 Review.
-
Associations Between Interleukin-10 Polymorphisms and Susceptibility to Sjögren's Syndrome: A Meta-Analysis.Int J Immunogenet. 2025 Feb;52(1):24-32. doi: 10.1111/iji.12702. Epub 2024 Nov 7. Int J Immunogenet. 2025. PMID: 39511968 Review.
Cited by
-
Tumor necrosis factor-alpha-308 gene promoter polymorphism associates with survival of cancer patients: A meta-analysis.Medicine (Baltimore). 2018 Nov;97(45):e13160. doi: 10.1097/MD.0000000000013160. Medicine (Baltimore). 2018. PMID: 30407345 Free PMC article. Review.
-
IL10-modified Human Mesenchymal Stem Cells inhibit Pancreatic Cancer growth through Angiogenesis Inhibition.J Cancer. 2020 Jul 9;11(18):5345-5352. doi: 10.7150/jca.38062. eCollection 2020. J Cancer. 2020. PMID: 32742480 Free PMC article.
-
Breast Cancer in Young Women: Status Quo and Advanced Disease Management by a Predictive, Preventive, and Personalized Approach.Cancers (Basel). 2019 Nov 14;11(11):1791. doi: 10.3390/cancers11111791. Cancers (Basel). 2019. PMID: 31739537 Free PMC article. Review.
-
Role of Genetic Polymorphisms -238 G>A and -308 G>A, and Serum TNF-α Levels in a Cohort of Mexican Pediatric Neuroblastoma Patients: Preliminary Study.Int J Mol Sci. 2024 Oct 1;25(19):10590. doi: 10.3390/ijms251910590. Int J Mol Sci. 2024. PMID: 39408920 Free PMC article.
-
A panel containing PD-1, IL-2Rα, IL-10, and CA15-3 as a biomarker to discriminate breast cancer from benign breast disease.Cancer Manag Res. 2018 Jun 26;10:1749-1761. doi: 10.2147/CMAR.S160452. eCollection 2018. Cancer Manag Res. 2018. PMID: 29983594 Free PMC article.
References
-
- Chenjiao Y, Zili F, Haibin C, Ying L, Sheng X, Lihua H, Wei D. IL-10 promoter polymorphisms affect IL-10 production and associate with susceptibility to acute myeloid leukemia. Pharmazie. 2013;68(3):201–6. - PubMed
-
- Howell MW, Rose-zerilli MJ. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 2007;137 Suppl 1:194–199 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical